Mesoblast Limited (NASDAQ:MESO) Receives Average Rating of "Buy" from Brokerages

Key Points

• Mesoblast Limited (NASDAQ:MESO) has received a consensus rating of "Buy" from five ratings firms, with an average price target of $18.00.
• Research analysts' ratings include one hold, two buy, and two strong buy recommendations for the stock.
• Institutional investors have increased their stakes in Mesoblast, with notable increases from firms like LPL Financial and Geode Capital Management, highlighting growing confidence in the company's future.

Mesoblast Limited (NASDAQ:MESO - Get Free Report) has earned a consensus recommendation of "Buy" from the five brokerages that are covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, two have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $18.00.

A number of brokerages have recently issued reports on MESO. Jefferies Financial Group downgraded shares of Mesoblast from a "buy" rating to a "hold" rating in a research report on Friday, July 18th. Canaccord Genuity Group raised Mesoblast to a "strong-buy" rating in a report on Tuesday, August 5th.

Institutional Trading of Mesoblast

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets increased its holdings in shares of Mesoblast by 86,566.7% in the fourth quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company's stock worth $51,000 after purchasing an additional 2,597 shares during the last quarter. Bank of America Corp DE increased its stake in Mesoblast by 1,503.3% in the 4th quarter. Bank of America Corp DE now owns 290,728 shares of the company's stock worth $5,756,000 after acquiring an additional 272,595 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Mesoblast by 1,174.2% during the 1st quarter. GAMMA Investing LLC now owns 85,513 shares of the company's stock worth $1,067,000 after acquiring an additional 78,802 shares in the last quarter. Quadrant Capital Group LLC boosted its position in shares of Mesoblast by 41.1% during the 4th quarter. Quadrant Capital Group LLC now owns 6,496 shares of the company's stock valued at $129,000 after acquiring an additional 1,891 shares during the last quarter. Finally, Summit X LLC grew its holdings in shares of Mesoblast by 36.0% in the first quarter. Summit X LLC now owns 198,163 shares of the company's stock valued at $2,473,000 after purchasing an additional 52,508 shares in the last quarter. 1.43% of the stock is currently owned by institutional investors.

Mesoblast Stock Up 1.6%

MESO stock traded up $0.23 during midday trading on Friday, reaching $14.93. 103,164 shares of the company's stock traded hands, compared to its average volume of 281,150. Mesoblast has a 52-week low of $6.00 and a 52-week high of $22.00. The company has a quick ratio of 0.63, a current ratio of 0.96 and a debt-to-equity ratio of 0.22. The stock's 50-day moving average is $12.72 and its 200 day moving average is $13.26.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.